Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
This "Golden" Technical Indicator is Triggering Across the Market
01:36pm, Thursday, 26'th Jan 2023 Zacks Investment Research
A Golden Cross is a simple, yet effective technical indicator. Andrew Rocco explains how to use it and relates it back to the current market.
Is Biogen Stock a Buy Now?
12:30pm, Thursday, 26'th Jan 2023 The Motley Fool
Its new drug might succeed where the company faltered in 2021.
This "Golden" Technical Indicator is Triggering Across the Market
09:47am, Thursday, 26'th Jan 2023
A Golden Cross is a simple, yet effective technical indicator. Andrew Rocco explains how to use it and relates it back to the current market.
Is Biogen Stock a No-Brainer Buy After Eli Lilly's Alzheimer's Disease Setback?
10:57am, Wednesday, 25'th Jan 2023 The Motley Fool
Lilly's FDA rejection puts Biogen and its partner Eisai in the driver's seat in the Alzheimer's disease drug market.
Biogen Inc. (BIIB) Stock Moves -0.02%: What You Should Know
11:00pm, Tuesday, 24'th Jan 2023 Zacks Investment Research
In the latest trading session, Biogen Inc. (BIIB) closed at $291.88, marking a -0.02% move from the previous day.
Why Biogen Inc. (BIIB) Could Beat Earnings Estimates Again
05:10pm, Tuesday, 24'th Jan 2023 Zacks Investment Research
Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Where Biogen Stands With Analysts
05:00pm, Tuesday, 24'th Jan 2023 Benzinga
Biogen (NASDAQ:BIIB) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
2
4
0
0
Last 30D
0
1
0
Why Biogen Inc. (BIIB) Could Beat Earnings Estimates Again
01:33pm, Tuesday, 24'th Jan 2023
Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
2 Stocks to Buy with Recent Fair Value Increases
08:00am, Tuesday, 24'th Jan 2023
Morningstar analysts just raised their intrinsic values on these names. 00:00 Introduction 01:02 Host Hotels & Resorts (HST) 01:38 Biogen Stock (BIIB) Susan Dziubinski: Morningstar analysts calculate
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
11:20am, Monday, 23'rd Jan 2023 Zacks Investment Research
Smart Beta ETF report for XBI
Eating these simple foods may slow Alzheimer's by a third
05:07pm, Saturday, 21'st Jan 2023 MarketWatch
New research shows that people who ate certain foods were less likely to get dementia.
Why the FDA didn't grant an approval to Lilly's Alzheimer's drug
02:19pm, Saturday, 21'st Jan 2023 MarketWatch
The regulator wants to see clinical data from at least 100 patients who have taken donanemab for a year
FDA Rejects Accelerated Nod to Lilly's (LLY) Alzheimer's Drug
05:52pm, Friday, 20'th Jan 2023 Zacks Investment Research
The FDA rejects Eli Lilly's (LLY) seeking accelerated approval of a new Alzheimer's drug, donanemab, due to the limited number of patients with at least 12 months of drug exposure data.
Tech Stocks Get Netflix Boost Amid Jittery Wider Market On Friday, Dow Stares At 4th Straight Loss
11:30am, Friday, 20'th Jan 2023 Benzinga
U.S. stocks look set for a positive start on Friday, reversing course from the sell-off seen in the past three sessions.
What Happened: Traders may have to contend with Fed speeches and housing mark
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
11:15pm, Thursday, 19'th Jan 2023 Zacks Investment Research
Biogen Inc. (BIIB) closed the most recent trading day at $280.13, moving -1.18% from the previous trading session.
